|
|||||
|
|
Lapatinib-induced hepatitis: a case report |
|
| Authors: | Peroukides Stavros Makatsoris Thomas Koutras Angelos Tsamandas Athanasios Onyenadum Adimchi Labropoulou-Karatza Chryssoula Kalofonos Haralabos |
| Affiliation: | Stavros Peroukides,Thomas Makatsoris,Angelos Koutras,Adimchi Onyenadum,Haralabos Kalofonos,Department of Medical Oncology,University Hospital of Patras,26500 Rio,Patras,Greece Athanasios Tsamandas,Department of Pathology,Greece Chryssoula Labropoulou-Karatza,Department of Internal Medicine,Greece |
| Abstract: | Lapatinib is an inhibitor of the tyrosine kinases of human epidermal growth factor receptor type 2 (HER2) and epidermal growth factor receptor type 1, with clinical activity in HER2-positive metastatic breast cancer. We present here a 60 year-old patient with metastatic breast cancer who presented with jaundice and increased serum aminotransferase levels and who had been treated with lapatinib for the previous 14 days. Laboratory tests excluded other causes of acute liver injury. Liver biopsy revealed lesio... |
| Keywords: | Lapatinib Hepatitis Hepatotoxicity Breast cancer Human epidermal growth factor receptor type 2 |
| 本文献已被 CNKI 维普 PubMed 等数据库收录！ | |